Skip to main content
. 2012 Dec 7;4(6):51. doi: 10.1186/alzrt154

Table 1.

Characteristics of subjects

Characteristic AD
(n = 78)
aMCI
(n = 59)
Normal Control
(n = 66)
P*
Demographic

 Age, y (mean, SD) 75.7 (8.4) 71.3 (8.5) 71.1 (8.3) 0.0005
 Female, N (%) 47 (60%) 28 (43%) 24 (36%) 0.017
 Education, y (mean, SD) 11.4 (2.8) 12.8 (3.5) 13.1 (2.7) 0.0005

Clinical

 Statin Use, N (%) 16 (21%) 17 (28.8%) 11 (17%) 0.26
 BMI (mean, SD) 25.4 (3.2) 25.6 (3.9) 24.6 (3.7) 0.33
 ESC score (mean, SD) 0.133 (0.110) 0.094 (0.102) 0.103 (0.078) 0.015
 Diabetes type 1 or 2, N (%) 6 (7.7%) 1 (1.7%) 3 (4.5%) 0.30
 History of heart disease, N (%) 8 (10.3%) 9 (15.3%) 7 (10.6%) 0.68
 Hachinski score (mean, SD) 2.6 (1.9) 2.5 (2.6) 0.7 (1.0) < 0.0001
 Scheltens score (mean, SD) 12.2 (9.9) 10.8 (10.8) 6.4 (5.7) 0.0021
 Wahlund score (mean, SD) 4.0 (2.7) 3.7 (2.8) 2.8 (1.7) 0.04
 Duration of symptoms, y (mean, sd) 2.5 (2.4) 3.1 (3.3) NA 0.63
 MMSE, mean (mean, SD) 23.8 (2.7) 28 (1.7) 29.1 (1.0) < 0.0001

Laboratory

 LpPLA2, nmol/min/ml (mean, SD) 197.1 (38.4) 205.5 (43.4) 195.4 (41.9) 0.34
 LDL, mmol/L (mean, SD) 2.9 (1.0) 2.9 (0.8) 3.0 (1.2) 0.79
 HDL, mmol/L (mean, SD) 2.0 (0.5) 1.8 (0.5) 1.7 (0.5) 0.005
 Total cholesterol:HDL ratio 3.0 (0.9) 3.2 (0.9) 3.5 (1.2) 0.012
 Homocysteine, Umol/L (mean, sd) 15.1 (5.4) 14.1 (7.9) 12.3 (3.4) 0.002
 HbA1c, % (SD) 5.6 (0.4) 5.6 (0.4) 5.5 (0.3) 0.43
CSF markers of AD
 Aβ42, pg/ml (mean, SD) 421.4 (147.6) 568.2 (251.7) 809.7 (260.5) < 0.0001
 CSF T-Tau, pg/ml (mean, SD) 698.5 (317.2) 417.2 (245.6) 308.0 (195.9) < 0.0001
 CSF P-Tau, pg/ml (mean, SD) 101.9 (58.0) 62.9 (27.9) 52.0 (21.6) < 0.0001

Genetic

APOE ε4-positive, N (%) 45 (58%) 30 (50.5%) 4 (6%) NA

*ANOVA for normally distributed continuous variables, Kruskal-Wallis test for non-normal continuous variables, Fisher's exact test for ordinal variables. † Control selection was not independent of APOE status.